← USPTO Patent Grants

Administration of Yunnan Baiyao or Xingnaojing in patients with moderate-to-severe traumatic brain injury and craniotomy

Grant US12582691B2 Kind: B2 Mar 24, 2026

Assignee

Lotus Biotech.com LLC

Inventors

Guoqiang Xing, Xiaodong Ma

Abstract

Clinically validated methods of administering Yunnan Baiyao or Xingnaojing can improve postoperative recovery and long-term clinical prognosis of patients with moderate-to-severe traumatic brain injury (TBI) and emergency craniotomy. Both medicinal methods are useful for minimizing or inhibiting the adverse impacts of secondary injury, oxidative damage and neuroinflammation associated with TBI, spinal cord injury, craniotomy/craniectomy, cerebral hemostasis and hemorrhage, coagulopathy, stroke, neural injury and neuroinflammation, and for promoting the long-term functional recovery and well-being of the patients with the afore-mentioned diseases.

CPC Classifications

A61K 36/9066 A61K 35/55 A61K 36/258 A61K 36/744 A61K 45/06 A61P 7/04 A61P 29/00

Filing Date

2022-07-12

Application No.

17812171

Claims

7